Cargando…

PPP1R14D promotes the proliferation, migration and invasion of lung adenocarcinoma via the PKCα/BRAF/MEK/ERK signaling pathway

Protein phosphatase 1 (PP1) inhibitors play a role in tumor progression through different mechanisms. Protein phosphatase 1 regulatory subunit 14D (PPP1R14D) is an inhibitor of PP1. However, the role of PPP1R14D in tumors and its mechanism of action are largely unknown. The purpose of the present st...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cao, Huijun, Wang, Zhiqiang, Wang, Ying, Ye, Lijuan, Li, Ruilei, Xue, Yuanbo, Li, Ke, Di, Tiannan, Li, Tao, Fan, Zonglin, Liu, Yanyan, Guo, Jiyin, Yao, Hong, Ge, Chunlei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9635868/ https://www.ncbi.nlm.nih.gov/pubmed/36263632 http://dx.doi.org/10.3892/ijo.2022.5443

Ejemplares similares

PPP6C negatively regulates oncogenic ERK signaling through dephosphorylation of MEK
por: Cho, Eunice, et al.
Publicado: (2021)

Knockdown of STIM1 expression inhibits non-small-cell lung cancer cell proliferation in vitro and in nude mouse xenografts
por: Ge, Chunlei, et al.
Publicado: (2019)

BRAF/MEK inhibitors promote CD47 expression that is reversible by ERK inhibition in melanoma
por: Liu, Fen, et al.
Publicado: (2017)

Architecture of autoinhibited and active BRAF/MEK1/14-3-3 complexes
por: Park, Eunyoung, et al.
Publicado: (2019)

Growth hormone receptor promotes breast cancer progression via the BRAF/MEK/ERK signaling pathway
por: Zhu, Xiaojue, et al.
Publicado: (2020)

Structures of BRAF–MEK1–14-3-3 sheds light on drug discovery
por: Sun, Qiu, et al.
Publicado: (2019)

Immunomodulatory Properties of BRAF and MEK Inhibitors Used for Melanoma Therapy—Paradoxical ERK Activation and Beyond
por: Jung, Thomas, et al.
Publicado: (2021)

O-GlcNAc on PKCζ Inhibits the FGF4-PKCζ-MEK-ERK1/2 Pathway via Inhibition of PKCζ Phosphorylation in Mouse Embryonic Stem Cells
por: Miura, Taichi, et al.
Publicado: (2017)

Over-expressed, N-terminally truncated BRAF is detected in the nucleus of cells with nuclear phosphorylated MEK and ERK
por: Hey, Fiona, et al.
Publicado: (2018)

K27-linked ubiquitination of BRAF by ITCH engages cytokine response to maintain MEK-ERK signaling
por: Yin, Qing, et al.
Publicado: (2019)

Leptin Inhibits Glucose Intestinal Absorption via PKC, p38MAPK, PI3K and MEK/ERK
por: El-Zein, Ola, et al.
Publicado: (2013)

Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma
por: Smalley, Keiran SM, et al.
Publicado: (2015)

Medical debulking with BRAF/MEK inhibitors in aggressive BRAF-mutant craniopharyngioma
por: Di Stefano, Anna Luisa, et al.
Publicado: (2020)

POU4F1 promotes the resistance of melanoma to BRAF inhibitors through MEK/ERK pathway activation and MITF up-regulation
por: Liu, Lin, et al.
Publicado: (2020)

BKCa participates in E2 inducing endometrial adenocarcinoma by activating MEK/ERK pathway
por: Wang, Fenfen, et al.
Publicado: (2018)

Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation
por: Lionetti, Marta, et al.
Publicado: (2015)

Remarkable response of BRAF(V600E)-mutated metastatic pancreatic cancer to BRAF/MEK inhibition: a case report
por: Li, Hong-Shuai, et al.
Publicado: (2021)

PKC-mediated phosphorylation and activation of the MEK/ERK pathway as a mechanism of acquired trastuzumab resistance in HER2-positive breast cancer
por: Scerri, Jeanesse, et al.
Publicado: (2022)

BRAF Mutations Occur Infrequently in Ovarian Cancer but Suggest Responsiveness to BRAF and MEK Inhibition
por: Campos, Maira P., et al.
Publicado: (2018)

TERT Expression Induces Resistance to BRAF and MEK Inhibitors in BRAF-Mutated Melanoma In Vitro
por: Delyon, Julie, et al.
Publicado: (2023)

Integrating BRAF/MEK inhibitors into combination therapy for melanoma
por: Smalley, K S M, et al.
Publicado: (2009)

BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients
por: Mackiewicz, Jacek, et al.
Publicado: (2018)

BRAF and MEK Inhibitors and Their Toxicities: A Meta-Analysis
por: Garutti, Mattia, et al.
Publicado: (2022)

Regulation of BRAF protein stability by a negative feedback loop involving the MEK–ERK pathway but not the FBXW7 tumour suppressor
por: Hernandez, Maria Aguilar, et al.
Publicado: (2016)

Phase I clinical trial of a novel autologous modified-DC vaccine in patients with resected NSCLC
por: Ge, Chunlei, et al.
Publicado: (2017)

Systemic Inflammation Increases the Susceptibility to Levodopa-Induced Dyskinesia in 6-OHDA Lesioned Rats by Targeting the NR2B-Medicated PKC/MEK/ERK Pathway
por: Yan, Aijuan, et al.
Publicado: (2021)

Regulator of G protein signalling 14 attenuates cardiac remodelling through the MEK–ERK1/2 signalling pathway
por: Li, Ying, et al.
Publicado: (2016)

Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers
por: Corcoran, Ryan B., et al.
Publicado: (2011)

Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models
por: Del Curatolo, Anais, et al.
Publicado: (2018)

Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma
por: Hamid, Omid, et al.
Publicado: (2019)

IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma
por: Patel, Hima, et al.
Publicado: (2021)

Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600–Mutant Tumors
por: Adashek, Jacob J., et al.
Publicado: (2022)

PPP1R14B Is a Prognostic and Immunological Biomarker in Pan-Cancer
por: Deng, Mingxia, et al.
Publicado: (2021)

BRAF/MEK double blockade in refractory anaplastic pleomorphic xanthoastrocytoma
por: Migliorini, Denis, et al.
Publicado: (2017)

MEK inhibitors in non-V600 BRAF mutations and fusions
por: Johnson, Douglas B., et al.
Publicado: (2020)

Tracking and blocking interdependencies of cellular BRAF-MEK oncokinase activities
por: Fleischmann, Jakob, et al.
Publicado: (2023)

Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2
por: Chen, Wenjing, et al.
Publicado: (2023)

A Predictive Model of Adaptive Resistance to BRAF/MEK Inhibitors in Melanoma
por: Ruiz, Emmanuelle M., et al.
Publicado: (2023)

Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial
por: Ascierto, Paolo A., et al.
Publicado: (2023)

Novel Variants of PPP2R1A in Catalytic Subunit Binding Domain and Genotype–Phenotype Analysis in Neurodevelopmentally Delayed Patients
por: Qian, Yanyan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_g0u1elrdfirv9afineue518km2